[{"orgOrder":0,"company":"Tranquis Therapeutics","sponsor":"Remiges Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Series A Financing","leadProduct":"TQS-168","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Tranquis Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Tranquis Therapeutics \/ Remiges Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Tranquis Therapeutics \/ Remiges Ventures"},{"orgOrder":0,"company":"Tranquis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"TQS-168","moa":"PGC-1a","graph1":"Neurology","graph2":"Phase I","graph3":"Tranquis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tranquis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tranquis Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tranquis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"TQS-168","moa":"PGC-1a","graph1":"Neurology","graph2":"Phase I","graph3":"Tranquis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tranquis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tranquis Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tranquis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"TQS-168","moa":"PGC-1a","graph1":"Neurology","graph2":"Phase I","graph3":"Tranquis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tranquis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tranquis Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Tranquis Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : TQS-168 is a PGC-1a-enhancing small molecule in development for the treatment of neurodegenerative, metabolic, and aging-related diseases in which PGC-1a modulation plays a critical role.

                          Brand Name : TQS-168

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 29, 2022

                          Lead Product(s) : TQS-168

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : TQS-168, a small molecule modulator of PGC-1a, for the treatment of amyotrophic lateral sclerosis (ALS). TQS-168 showed survival and functional benefits in various animal models of neurodegenerative disease, including ALS and Parkinson’s disease.

                          Brand Name : TQS-168

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 21, 2022

                          Lead Product(s) : TQS-168

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The data from our Phase 1 study of TQS-168, a small molecule modulator of PGC-1a demonstrate that target plasma exposures can be achieved at dose levels that are well tolerated.

                          Brand Name : TQS-168

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 02, 2022

                          Lead Product(s) : TQS-168

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The financing will support company's novel platform based on groundbreaking research from the laboratory of Professor Edgar Engleman, MD, at Stanford University indicating that myeloid immune cell dysfunction underlies a variety of nervous system disorde...

                          Brand Name : TQS-168

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 09, 2020

                          Lead Product(s) : TQS-168

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Remiges Ventures

                          Deal Size : $30.0 million

                          Deal Type : Series A Financing

                          blank